INTRODUCTION {#s1}
============

MicroRNAs (miRNAs) are 18--25 nucleotides length of noncoding single-stranded RNAs that post-transcriptionally silence gene expression through degradation of messenger RNA (mRNA) targets and (or) block protein translations of these targets \[[@R1]\]. MiRNA are widely expressed in the yeast, animal and plant genomes and have been implicated in many important physiologic and pathologic processes such as cell proliferation, differentiation, migration, autophagy and apoptosis, etc \[[@R2]\]. Dysregulation of miRNA expression has been found to have relevance not only to tumorigenesis, but also to neurological, cardiovascular, developmental and other diseases \[[@R3]\].

Single nucleotide polymorphisms (SNPs) are a type of polymorphism involving variation of a single base pair. Recent DNA sequencing has revealed SNPs in miRNA coding genes, both in miRNA seeding and loop regions \[[@R4], [@R5]\]. SNPs present in the miRNA gene regions can affect their transcription and maturation processing through their transcripts (pri-miRNA, pre-miRNA), which lead to aberrant mature miRNA expression levels \[[@R6]\]. In addition, SNPs in seeding regions of miRNA genes may influence miRNA-mRNA interactions and eventually alter functions of miRNAs on targets \[[@R6]\]. Accumulating studies showed that SNPs in miRNAs or their precursors are marked as novel genetic variations which may modify the cancer susceptibilities \[[@R7]\].

The oncogenic miR-27 is known to regulate pathogenesis in numerous types of cancer, including breast cancer, esophageal cancer, gastric cancer and lung cancer \[[@R3], [@R8]--[@R12]\]. Previously, a common single nucleotide polymorphism in pre-miR-27a, rs895819, has been demonstrated to be associated with decreased risk of breast cancer risk, but later studies showed conflicting associations \[[@R13]--[@R20]\]. Some other epidemiological studies indicated that rs895819 was associated with increased risk of gastric cancer, and the genotypes of rs895819 was correlated with miR-27a expression levels, however, other studies showed lack association of rs895819 with gastric cancer risk \[[@R21]--[@R27]\]. Meta-analysis studies revealed that rs895819 was a functional SNP and may have some relation to colorectal cancer susceptibility, especially in Asians \[[@R28]\]. Generally, the current available data were inconsistent about the effects of rs895819 on carcinogenesis in different cancers \[[@R28], [@R29]\], this discrepancy maybe partially attributed to the heterogeneity of the cancer subtype, small sample size, and ethnicity of the study population. Therefore, it is necessary to conduct a comprehensive review and meta-analysis of published data from all eligible studies on the association of rs895819 with cancer risk. In this study, we performed an update meta-analysis by including more recent publications to improve the efficiency and to drive a more precise estimation of the association between rs895819 SNP and cancer risks.

RESULTS {#s2}
=======

Characteristics of studies {#s2_1}
--------------------------

Fifty-eight abstracts were retrieved after the search "miR-27a", "polymorphism" and "cancer", and 27 articles were identified as eligible studies. Among the 58, 10 articles were pooled analysis, commentary \[[@R32]--[@R41]\] and 3 articles were review papers \[[@R28], [@R29], [@R42]\], and 3 reports were cancer biology experimental studies \[[@R43]--[@R45]\]. Ten studies were excluded because they reported non-cancer disease \[[@R46]--[@R55]\]. Five studies were excluded due to not related to miR-27a polymorphism, or no controls \[[@R56]--[@R60]\]. We also included 6 eligible articles by manual searching \[[@R16], [@R20], [@R25], [@R61]--[@R63]\], in which the study by Li *et al.* included two independent case-control studies \[[@R13]\] and the pooled analysis by Xu *et al.* presented efficient case-control study data. Totally, 34 eligible studies from 33 articles met the inclusion criteria were included in the meta-analysis (Figure [1](#F1){ref-type="fig"}).

![Flow diagram of studies identification](oncotarget-08-75336-g001){#F1}

Totally, 15,388 cases and 18,704 controls were included from 34 studies, including eight studies for breast cancer with 3,967 cases and 5,013 controls, eight for colorectal cancer with 2,381 cases and 3,058 controls, eight for gastric cancer with 4,016 cases and 4,782 controls, three for lung cancer with 1,284 cases and 1,393 controls, and two for esophageal cancer with 1,488 cases and 1,652 controls. For other cancers, there was only one study was included for each type of cancer, including live cancer \[[@R61]\], nasopharyngeal cancer \[[@R64]\], renal cancer \[[@R64]\], cervical cancer \[[@R65]\] and prostate cancer \[[@R66]\]. For ethnic distribution, there were twenty-seven studies of Asian origin, and seven studies on Caucasian descent. For the study design, the sources of controls from 8 studies were population-based, and the others were hospital-based. The genotype frequencies in the control group for each included study were consistent with HWE except three studies \[[@R14], [@R62], [@R67]\]. The selected study characteristics were listed in Table [1](#T1){ref-type="table"}.

###### Characteristics of studies included in the meta-analysis

  Author         Year   Origin    Ethnicity    Cancer type             Sample size (case/control)   HWE     MAF     Design   Genotyping method
  -------------- ------ --------- ------------ ----------------------- ---------------------------- ------- ------- -------- -------------------
  Yang R         2010   Germany   German       Breast cancer           1189/1416                    0.142   0.340   PB       DNA Sequencingg
  Zhang P        2011   China     Chinese      Breast cancer           376/190                      0.605   0.258   PB       MassARRAY
  Catucci I      2012   Italy     Italian      Breast cancer           1025/1593                    0.051   0.297   PB       TaqMan
  Zhang M        2012   China     Chinese      Breast cancer           245/243                      0.122   0.467   PB       PCR-RFLP
  Zhang N        2013   China     Chinese      Breast cancer           264/255                      0.446   0.261   HB       TaqMan
  Wang P         2014   China     Chinese      Breast cancer           107/219                      0.537   0.237   HB       PCR-RFLP
  Qi P           2015   China     Chinese      Breast cancer           321/290                      0.686   0.433   PB       TaqMan
  Morales S      2016   America   American     Breast cancer           440/807                      0.017   0.280   HB       TaqMan
  Sun Q          2010   China     Chinese      Gastric cancer          304/304                      0.053   0.327   HB       PCR-RFLP
  Zhou Y         2012   China     Chinese      Gastric cancer          295/413                      0.941   0.280   HB       MALDI-TOF
  Xu Q           2013   China     Chinese      Gastric cancer          222/305                      0.437   0.252   HB       DNA Sequencingg
  Yang Q         2014   China     Chinese      Gastric cancer          592/978                      0.517   0.383   PB       TaqMan
  Kupcinskas J   2014   Latvia    Lithuanian   Gastric cancer          363/350                      0.151   0.320   HB       TaqMan
  Song B         2014   China     Chinese      Gastric cancer          278/278                      0.110   0.329   HB       TaqMan
  Jiang J        2016   China     Chinese      Gastric cancer          895/988                      0.447   0.260   HB       MassARRAY
  Xu Q           2017   China     Chinese      Gastric cancer          1067/1166                    0.161   0.247   HB       MALDI-TOF MS
  Zhang M        2012   China     Chinese      Colorectal cancer       463/468                      0.351   0.246   PB       PCR-RFLP
  Hezova R       2012   Czech     Caucasian    Colorectal cancer       197/212                      0.867   0.340   HB       TaqMan
  Wang Z         2014   China     Chinese      Colorectal cancer       205/455                      2.156   0.524   HB       TaqMan
  Kupcinskas J   2014   Latvia    Lithuanian   Colorectal cancer       191/428                      0.235   0.303   HB       TaqMan
  Cao Y          2014   China     Chinese      Colorectal cancer       254/238                      0.089   0.326   HB       PCR--RFLP
  Wu R           2014   China     Chinese      Colorectal cancer       151/283                      0.016   0.201   HB       DNA Sequencingg
  Bian Q         2015   China     Chinese      Colorectal cancer       412/412                      0.389   0.301   HB       TaqMan
  Jiang Y        2016   China     Chinese      Colorectal cancer       508/562                      0.053   0.313   HB       TaqMan
  Wei J          2013   China     Chinese      Esophageal Cancer       379/377                      0.322   0.264   HB       MALDI-TOF MSS
  Zhang J        2014   China     Chinese      Esophageal Cancer       1109/1275                    0.226   0.253   PB       PCR
  Ma J Y         2015   China     Chinese      Lung cancer             542/557                      0.015   0.308   HB       TaqMan
  Yin Z          2015   China     Chinese      Lung cancer             167/228                      0.282   0.228   HB       TaqMan
  Yin Z          2016   China     Chinese      Lung cancer             575/608                      0.199   0.270   HB       TaqMan
  Li P           2011   China     Chinese      Nasopharyngeal Cancer   801/1022                     0.658   0.295   HB       SNP Stream
  Shi D          2011   China     Chinese      Renal cancer            594/600                      0.373   0.302   HB       TaqMan
  Li P           2011   China     Chinese      Liver Cancer            401/459                      0.751   0.285   HB       SNP Stream
  Xiong X D      2014   China     Chinese      Cervical Cancer         103/417                      0.255   0.261   HB       DNA Sequencing
  Nikolic Z      2015   Serbia    Serbian      Prostate cancer         353/308                      0.101   0.284   HB       PCR--RFLP

Abbreviations: HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; HB, Hospital based controls; PB, population based controls; PCR, Polymerase chain reaction; RFLP, Restriction fragment length polymorphism; MALDI-TOF, Matrix-assisted laser desorption/ ionization- time of flight.

Quantitative synthesis {#s2_2}
----------------------

Table [2](#T2){ref-type="table"} presents the meta-analysis results for all cancers. By pooling all the studies, rs895819 was associated with increased risk of cancer in recessive (OR = 1.15; 95% CI = 1.02--1.29) but not other model (Figures [2](#F2){ref-type="fig"}--[6](#F6){ref-type="fig"}). In the subgroup analyses, rs895819 was associated with increased risk of cancer in homogeneous (OR = 1.17; 95% CI = 1.01--1.36) or recessive (OR = 1.18; 95% CI = 1.03--1.35) model in Asians, but no association of rs895819 with cancer risk was found in Caucasians. (Table [2](#T2){ref-type="table"}). Interestingly, the \[G\] allele of rs895819 was significantly associated with decreased risk of breast cancer (OR = 0.91; 95% CI = 0.86--0.97). However, rs895819 was associated with increased risk of colorectal cancer in homogeneous (OR = 1.56; 95% CI = 1.31--1.85), recessive (OR = 1.53; 95% CI = 1.30--1.79) or additive model (OR = 1.19; 95% CI = 1.09--1.30), and with increased risk of lung cancer in recessive model (OR = 1.43; 95% CI = 1.00--2.04). In addition, rs895819 was not associated with risk of esophageal cancer or gastric cancer. For other types of cancers, pooled analysis showed lack of association between rs895819 and cancer risk, and we did not perform a meta-analysis for each cancer since only one study was included for different type cancer. In stratified analysis by the sources of controls, the rs895819 was significantly associated with increased cancer risk in homogeneous (OR = 1.21; 95% CI = 1.03--1.42), or recessive (OR = 1.21; 95% CI = 1.04--1.41) model when pooling twenty-six hospital-based case-control studies, but no association was found when pooling eight population-based studies.

###### Stratified analysis of the association between miR-27a polymorphisms and cancer risk

  **Groups**           ***n***^a^   **Heterogenous**    **Homogenous**   **Dominant**            **Recessive**   **Additive**                                                                              
  -------------------- ------------ ------------------- ---------------- ----------------------- --------------- ------------------- ---------- ----------------------- ---------- ----------------------- ----------
  All                  34           0.95 (0.85--1.06)   \< 0.001         1.13 (1.00--1.29)       \< 0.001        0.99 (0.91--1.09)   \< 0.001   **1.15 (1.02--1.29)**   \< 0.001   1.03 (0.96--1.10)       \< 0.001
   Cancer types                                                                                                                                                                                            
   Breast cancer       8            0.93 (0.77--1.11)   0.002            0.88 (0.76--1.02)       0.834           0.91 (0.80--1.05)   0.052      0.90 (0.77--1.05)       0.351      **0.91 (0.86--0.97)**   0.682
   Gastric cancer      8            0.94 (0.66--1.34)   \< 0.001         1.00 (0.74--1.37)       0.001           0.97 (0.72--1.31)   \< 0.001   1.08 (0.83--1.40)       0.008      1.00 (0.84--1.19)       \< 0.001
   Colorectal cancer   8            0.97 (0.78--1.20)   0.005            **1.56 (1.31--1.85)**   0.758           1.10 (0.94--1.29)   0.067      **1.53 (1.30--1.79)**   0.582      **1.19 (1.09--1.30)**   0.351
   Lung cancer         3            0.95 (0.81--1.12)   0.416            1.41 (0.92--2.15)       0.144           1.05 (0.84--1.31)   0.142      **1.43 (1.00--2.04)**   0.219      1.12 (0.89--1.40)       0.038
   Esophageal cancer   2            1.03 (0.89--1.19)   0.775            0.88 (0.55--1.43)       0.140           1.02 (0.88--1.17)   0.479      0.88 (0.55--1.40)       0.147      0.99 (0.86--1.14)       0.247
   Other types         5            0.95 (0.75--1.20)   0.008            1.18 (0.78--1.79)       0.008           0.99 (0.77--1.27)   0.002      1.18 (0.83--1.68)       0.034      1.03 (0.84--1.26)       0.001
  Ethnic                                                                                                                                                                                                   
   Asian               27           0.96 (0.84--1.10)   \< 0.001         **1.17 (1.01--1.36)**   \< 0.001        1.01 (0.90--1.14)   \< 0.001   **1.18 (1.03--1.35)**   \< 0.001   1.04 (0.97--1.13)       \< 0.001
   Caucasian           7            0.91 (0.80--1.02)   0.146            0.98 (0.79--1.22)       0.110           0.92 (0.82--1.03)   0.131      1.03 (0.84--1.26)       0.124      0.96 (0.87--1.05)       0.114
  Source of controls                                                                                                                                                                                       
   HB                  26           0.97 (0.89--1.07)   \< 0.001         **1.21 (1.03--1.42)**   \< 0.001        1.02 (0.93--1.12)   \< 0.001   **1.21 (1.04--1.41)**   \< 0.001   1.06 (0.98--1.14)       \< 0.001
   PB                  8            0.91 (0.67--1.24)   \< 0.001         0.92 (0.81--1.05)       0.736           0.92 (0.72--1.18)   \< 0.001   1.01 (0.87--1.16)       0.222      0.94 (0.84--1.06)       \< 0.001

^a^Number of comparisons.

^b^The crude OR and 95% CI were calculated based on the genotype frequencies.

^c^*P* value of *Q*-test for heterogeneity analysis.

![Forest plots of heterozygote for meta-analysis on the association of rs895819 with cancer risk\
The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.](oncotarget-08-75336-g002){#F2}

![Forest plots of homozygote model for meta-analysis on the association of rs895819 with cancer risk\
The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.](oncotarget-08-75336-g003){#F3}

![Forest plots of dominant model for meta-analysis on the association of rs895819 with cancer risk\
The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.](oncotarget-08-75336-g004){#F4}

![Forest plots of recessive model for meta-analysis on the association of rs895819 with cancer risk\
The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.](oncotarget-08-75336-g005){#F5}

![Forest plots of additive model for meta-analysis on the association of rs895819 with cancer risk\
The squares and horizontal lines correspond to OR and 95% CI of specific study, and the area of squares reflects study weight (inverse of the variance). The diamond represents the pooled OR and its 95% CI.](oncotarget-08-75336-g006){#F6}

Next, we performed subgroup analyses for specific type of cancer. As to breast cancer, except for recessive model, rs895819 is associated with reduced cancer risk in Caucasians but not Asians ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). For cancers from digestive system, we found significant association between rs895819 and increased risk of cancers from all digestive system when pooling 19 studies on esophageal, gastric, colorectal and liver cancers in recessive (OR = 1.23; 95% CI = 1.06--1.43) or homogeneous model (OR = 1.20; 95% CI = 1.01--1.43). This association remained in digestive tracts when pooling 18 studies on esophageal, gastric and colorectal cancers in recessive (OR = 1.24; 95% CI, 1.06--1.45) or homogeneous model (OR = 1.20; 95% CI = 1.00--1.44). However, no association was found between rs895819 and risk of upper aero digestive tract cancers when pooling 10 studies on esophageal and gastric cancers. For gastric cancer, rs895819 was not associated with risk of gastric cancer in Asians when pooling 7 studies. For colorectal cancer, we observed that rs895819 were associated with increased risk of colorectal cancer in Asians in homogenous, recessive or additive model, but no association was found in Caucasians.

Sensitivity analysis and publication bias {#s2_3}
-----------------------------------------

When pooling all eligible studies, sensitivity analysis showed that exclusion of each study did not influence the result in specific genotype comparison for rs895819 except dominant model, suggesting that the results of synthetic analysis were robust for other each model ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

The Begg's test showed that the *P* value of rs895819 was 0.173, 0.553, 0.097, 0.767 or 0.192 for heterozygous, homozygous, dominant recessive and additive model, respectively, while the corresponding funnel plots showed symmetric distribution ( Figure [7](#F7){ref-type="fig"}). The Egger's test also showed that all the *P* values of rs895819 was 0.405, 0.293, 0.085, 0.941 or 0.053 for heterozygous, homozygous, dominant recessive and additive model, respectively, suggesting that there was no significant publication bias in the present study.

![Funnel plots showed symmetric or asymmetric distribution\
Log OR was plotted against the standard error of log OR for studies on rs895819 in heterozygous (**A**), homozygous (**B**), dominant (**C**), recessive (**D**) or additive model (**E**). The dots represent specific studies for the indicated association.](oncotarget-08-75336-g007){#F7}

DISCUSSION {#s3}
==========

In this study, we performed an update meta-analysis and found that rs895819 was associated with increased cancer risk in recessive model when including 34 studies of all cancers (15,388 cases and 18,704 controls), and this association remained in Asians but not Caucasians. Interestingly, the \[G\] allele of rs895819 played protective role on breast cancer, but the rs895819 was associated with increased risk of colorectal cancer or lung cancer in recessive model. In addition, no association was found between rs895819 and risk of gastric cancer or esophageal cancer.

Based on 17 case-control studies with 7,813 cases and 9,602 controls, our previous meta-analysis did not suggest any association between rs895819 and cancer susceptibility, while rs895819 was associated with a reduced cancer risk in heterozygous, dominant or additive model in Caucasians but not in Asians \[[@R33]\]. By pooling 19 studies (17 articles) involving 7,800 cases and 9,060 controls, a recent study by Feng et al., failed to find any associations between rs895819 polymorphism and cancer risk, while statistically significantly reduced cancer risks were found among Asians for dominant contrast and a subtly decreased risk was observed in the Caucasian population for heterozygous or additive contrast \[[@R29]\]. In the present study, by including 34 studies with almost twice number of subjects, we found that rs895819 was associated with increased cancer risk in recessive model for all population and Asians, but not Caucasians, suggesting a possible ethnic difference in the genetic and the environmental factors. The discrepancy between these meta-analyses might be due to sample size of pooled studies, and whether the risk of rs895819 on cancer depends on ethnicity should be confirmed by more studies.

When stratified by the cancer type, our data was consistent with previous meta-analysis reports that the \[G\] allele of rs895819 was associated with decreased risk in breast cancer for all population and Caucasians, but not Asians \[[@R29], [@R33]\]. For colorectal cancer, the study by Liu et al., pooling seven studies with 2,230 cases and 2,775 controls provided a moderate evidence for the association between rs895819 and increased risk of colorectal cancer under multiple genetic models for all population and Asians, but not Caucasians \[[@R28]\]. By including one more study, our data showed consistent findings. However, no significant association was found in cancers from upper aero digestive tracts, stomach or esophagus. As to lung cancer, we for the first time showed an association of rs895819 with increased risk of lung cancer in dominant model although the included studies were very limited. These findings suggested distinct effects of rs895819 on carcinogenesis in different types of cancers.

Generally, miR-27a, as an onco-miR, exhibits its oncogenic activity through dysregulating its downstream targets, and plays critical roles in the pathogenesis of multiple cancer types, e.g., cancer cell clonogenic growth and metastatic abilities \[[@R68]--[@R70]\]. Although the binding of the mature miRNA to target mRNAs may not be influenced by the rs895819 since rs895819 is not located in seeding sites \[[@R26]\], polymorphisms in the loop of pre-miRNAs could influence mature miRNAs processing and the expression levels of their mature forms \[[@R71]\]. Previous studies showed that rs895819 was positive associated with serum expression of mature miR-27a in gastric cancer patients \[[@R23], [@R24]\], but the molecular mechanism on regulation of miR-27a expression by rs895819 has not been investigated. It remains unclear whether rs895819 affected the processing of miR-27a maturation or/and expression of mature miR-27a. Our study showed distinct effects of rs895819 on cancer risk in different types of cancers, e.g., reduced risk of breast cancer *vs*. increased risk of colorectal or lung cancer, suggesting various roles of rs895819 in different cancer development since pre-miRNA is processed into mature miRNA via complex mechanisms.

The major limitation of this study is the heterogeneity for the rs895819 among these studies on different ethnic populations, even with same type cancer, and different types of cancers. The heterogeneity may come from various factors, such as diversity in characteristics of subjects, differences in the study population and study design, genetic susceptibility to different cancers, and different genotyping strategies. To eliminate heterogeneity, we performed subgroup analyses with a random-effects model to pool the studies when the significant heterogeneity was present. Secondly, we pooled the data based on unadjusted information without of considering the combination genetic factors together with environmental exposures due to lack of individual data for a more precise analysis. Thirdly, in some subgroup analyses, e.g., lung cancer, limited studies included may lead to reduced statistical power. Fourthly, sensitivity analysis showed that exclusion of one of few studies influenced the result in dominant model of genotype comparison for rs895819. This may be due to boardline significance of the association. Fifthly, our findings on the association of rs895819 with risk of specific cancer were mathematically significant, but the real effects of rs895819 on specific cancer risk in real SNP model await further investigations. Finally, our Egger's and Begg's test showed that slight publication bias exists, because only published studies in English or Chinese were included in this meta-analysis, which might affect the results.

In summary, current data suggest that rs895819 may contribute to increased susceptibility to colorectal and lung cancers, but appears as a protective factor for breast cancer. Since the studies on specific cancer included in this meta-analysis were still limited, the explanation of the current findings should be with caution and further well-designed studies with larger populations are required to clarify the distinct effects of rs895819 on cancer development in different types of cancers.

MATERIALS AND METHODS {#s4}
=====================

Identification and eligibility of relevant studies {#s4_1}
--------------------------------------------------

To identify the studies on the relationship between *miR-27a* polymorphism and cancer risk, we conducted systemic literature searching by retrieving databases and manual searching. Firstly, the PubMed databases up to February 2017 were searched using the following keywords: "miR-27a", "polymorphism" and "cancer". Additional manual searches were performed from other databases, e.g., Web of Science, China National Knowledge Infrastructure (CNKI), and references of review articles or original studies on this topic. The eligible studies met the following criteria: (a) case-control study, (b) available genotype frequency for the SNP investigated, and (c) sufficient data to estimate an odds ratio (OR) with corresponding 95% confidence interval (CI).

Data extraction {#s4_2}
---------------

Two investigators (M.C and W.F.) independently reviewed the studies included, extracted data and reached a consensus on all of the items if discrepancy existed. The following information of each study was extracted: first author and year of article, country of origin, ethnicity of subjects, cancer types, number of cases and controls, Hardy-Weinberg equilibrium (HWE) test for the genotype frequency of controls, minor allele frequencies (MAF) of the controls, source of controls and genotyping method. The ethnicity descents were categorized as Asian and Caucasian, and the cancer types were grouped as breast cancer, colorectal cancer, gastric cancer, lung cancer, esophageal cancer and others, and the sources of controls were defined as population-based (HB) or hospital-based (PB) respectively.

Statistical analysis {#s4_3}
--------------------

The Hardy-Weinberg equilibrium (HWE) was tested by the chi-square goodness of fit test. The crude ORs with 95% CIs were used to assess the strength of association between the *miR-27a* polymorphism rs895819 and cancer risk. Firstly, the risks of the AG and GG genotypes on cancer were estimated when comparing with the reference AA homozygote. Secondly, the risks of (AG + GG *vs*. AA) and (GG *vs*. AA + AG) on cancer were evaluated, assuming dominant and recessive effects of the variant GG allele, respectively. Thirdly, the effect of \[G\] allele on cancer risk were examined by comparing with the reference \[A\] allele (additive model). Stratified analyses were conducted by ethnicities of subjects, types of cancer and sources of controls. For the specific cancer, subgroup analyses were performed by ethnicity as well. Potential heterogeneity was evaluated by the I^2^-based *Q*-test. A random-effects (DerSimonian-Laird method) was used to calculate pooled effect estimates. Both Egger's test \[[@R30]\] and Begg's test \[[@R31]\] were applied to examine the publication bias for the overall pooled analyses of rs895819. In addition, Begg's funnel plots were drawn and the asymmetries of the funnel plots were applied to evaluate potential publication bias. For the one-way sensitivity analysis, each study was excluded each time, and the new pooled results reflected the influence of the deleted study to the overall summary OR. All analyses were carried out with Stata software (StataCorp LP, College Station, TX), and the statistical tests were considered statistically significant at *P* value \< 0.05 (two-sided).
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